Development · 9 Sep 2026

The proposed 100-200% US tariffs on generic drugs could raise medicine prices or cause shortages, as drugmakers may struggle to absorb costs or shift production without firm commitments and support.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

financialexpress.com9 Sep 2026

A single act of reporting so far, corroborating sources join this record as they publish.

Lupin

₹2,031.20

▲ +0.05%

Close (EOD), as of 1 Oct 2026 · source

Lupin: results, dividends, orders, the full cited record →

More on Lupin

Pharma stocks are picking up pace, with the sector continuing to show a strong overall technical setup despite the possibility of short-term profit booking.

2 Oct 2026 · 1 publisher

Indian pharmaceutical stocks gained in morning trade on Tuesday after the United States announced a zero-duty framework for select speciality medicines and related components originating from India and 19 other partner jurisdictions.

29 Sep 2026 · 1 publisher

Lupin has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway.

29 Sep 2026 · 1 publisher

Lupin Limited has secured the US Food and Drug Administration (FDA) tentative nod to market Bristol Myers Squibb’s blockbuster blood thinner Eliquis generic alternative.

29 Sep 2026 · 1 publisher

Market expert Aditya Agarwal flagged beaten-down pharma names such as Dr. Reddy’s and Lupin as seeing fresh buying interest at lower levels.

21 Sep 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.